The effect of treatment with BRX-220, a co-inducer of heat shock proteins, on sensory fibers of the rat following peripheral nerve injury.
In this study, we examined the effect BRX-220, a co-inducer of heat shock proteins, in injury-induced peripheral neuropathy. Following sciatic nerve injury in adult rats and treatment with BRX-220, the following features of the sensory system were studied: (a) expression of calcitonin gene-related peptide (CGRP); (b) binding of isolectin B4 (IB4) in dorsal root ganglia (DRG) and spinal cord; (c) stimulation-evoked release of substance P (SP) in an in vitro spinal cord preparation and (d) nociceptive responses of partially denervated rats. BRX-220 partially reverses axotomy-induced changes in the sensory system. In vehicle-treated rats there is a decrease in IB4 binding and CGRP expression in injured neurones, while in BRX-220-treated rats these markers were better preserved. Thus, 7.0 +/- 0.6% of injured DRG neurones bound IB4 in vehicle-treated rats compared to 14.4 +/- 0.9% in BRX-220-treated animals. Similarly, 4.5 +/- 0.5% of DRG neurones expressed CGRP in the vehicle-treated group, whereas 9.0 +/- 0.3% were positive in the BRX-220-treated group. BRX-220 also partially restored SP release from spinal cord sections to electrical stimulation of primary sensory neurones. Behavioural tests carried out on partially denervated animals showed that BRX-220 treatment did not prevent the emergence of mechanical or thermal hyperalgesia. However, oral treatment for 4 weeks lead to reduced pain-related behaviour suggesting either slowly developing analgesic actions or enhancement of recovery processes. Thus, the morphological improvement seen in sensory neurone markers was accompanied by restored functional activity. Therefore, treatment with BRX-220 promotes restoration of morphological and functional properties in the sensory system following peripheral nerve injury.
Kalmar
B
B
Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London WC1N 3BG, UK. b.kalmar@ucl.ac.uk
Greensmith
L
L
Malcangio
M
M
McMahon
S B
SB
Csermely
P
P
Burnstock
G
G
D000818:Animals; D019771:Axotomy; D015153:Blotting, Western; D015740:Calcitonin Gene-Related Peptide / Q000096:biosynthesis; D004558:Electric Stimulation; D005727:Ganglia, Spinal / Q000187:drug effects / Q000502:physiology; D018840:HSP70 Heat-Shock Proteins / Q000187:drug effects; D006898:Hydroxylamines / Q000494:pharmacology*; D037102:Lectins / Q000378:metabolism; D008297:Male; D009475:Neurons, Afferent / Q000187:drug effects* / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009924:Organ Culture Techniques; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012584:Sciatic Nerve / Q000502:physiology*; D013116:Spinal Cord / Q000187:drug effects / Q000502:physiology; D013127:Spinal Nerves / Q000502:physiology; D013373:Substance P / Q000096:biosynthesis / Q000187:drug effects
D018840:HSP70 Heat-Shock Proteins; D006898:Hydroxylamines; D037102:Lectins; D018696:Neuroprotective Agents; D013373:Substance P; C486387:arimoclomol; D015740:Calcitonin Gene-Related Peptide